Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced that The New England Journal of Medicine published results from its Phase 3 HERIZON-GEA-01 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE